© 2020 Marker Therapeutics, Inc.
…In multiple industry-related media Dr Glynn Wilson discusses status of clinical programs and advancement from phase 1 to phase 2 trials
SEATTLE, Nov. 24, 2014 /PRNewswire/ — TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed.
…Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design
SEATTLE, WASHINGTON, November 18, 2014 — TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune’s proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.